Key Takeaways Biotech core revenues rose 6% YoY in Q2, led by strong bioprocessing demand.Orders in bioprocessing are up for eight straight quarters, signaling solid momentum.Discovery and medical sales declined on weaker research equipment demand.Danaher Corporation’s (DHR) Biotechnology segment continues to play an important role in its overall growth. In the second quarter of 2025, the segment’s core revenues rose 6% on a year-over-year basis, fueled by sustained momentum in the bioprocessing business.An ...